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Abstract: Detection of human epidermal growth factor receptor 2 gene (HER2, also known as erbB2) expression is 
a preparatory process to decide a treatment strategy for breast cancer patients. 20-30% of breast cancer patients 
have HER2 overexpression, and they usually show poor recovery rate. For detection of HER2 expression, immuno-
histochemistry (IHC) and fluorescence in situ hybridization (FISH) methods are conventionally used. Although these 
methods are accurate and reliable, their time-consuming process and high cost need a concise method with high 
sensitivity and accuracy. As a complementary method to the current IHC/FISH standard techniques, PCR-based 
methods have been developed. Here we employed a quantitative PCR method to detect HER2 expression in one 
hundred ninety nine formalin-fixed and paraffin-embedded (FFPE) breast cancer tissue samples from the patients 
treated over two years at the Yonsei University Severance Hospital, Republic of Korea. Relative expression of HER2 
mRNA in the FFPE samples was analyzed using a quantitative RT-PCR (RT-qPCR) method and the obtained HER2 
expression levels were compared with those from IHC/FISH methods. Our results show that the RT-qPCR method 
was highly concordant with IHC/FISH methods for detecting HER2 expression. Overall sensitivity and specificity of 
the BrightGen HER2 RT-qDx assay kit (Syantra, Calgary, Canada), which is a kit we used for RT-qPCR analyses, were 
93.0% and 89.8% (P < 0.0001), respectively. The diagnostic cut-off value of HER2 RT-qDx for the clinical samples 
was determined by likelihood ratio, among which the highest likelihood ratio of relative HER2 mRNA levels was over 
105.5 (AUC = 0.9466) with the highest sensitivity and specificity. Our study indicates that quantification of HER2 
mRNA expression with the RT-qPCR could be an alternative method of conventional IHC/FISH methods.
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Introduction
Breast cancer remains the most common and 
second deadliest cancer in women. In spite of 
the high incidence of breast cancer, the surviv-
al rate of patients who have been diagnosed 
and treated in the initial stages is increasing 
[1]. The World Health Organization (WHO) esti-
mates that worldwide, more than 508,000 
women died in 2011 due to breast cancer. In 
the Republic of Korea, 13,460 new incidence 
of breast cancer were reported for a year of 
2010 [2].
The human epidermal growth factor receptor 2 
gene (HER2, also known as erbB2) has been 
regarded a critical factor for diagnosis and 
effective treatment of breast cancer patients 
[3]. It is known that approximately 20~30% of 
breast cancer patients have over-expression of 
the HER2 gene, and these patients are known 
to show poor prognosis [4]. Genomic alterations 
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of proto-oncogene HER2 are associated with 
poor prognosis and a more aggressive tumor 
phenotype. Thus, a HER2-positive status indi-
cates a poor prognosis and shorter overall sur-
vival time [5]. Patients with HER2 amplification 
or over-expression are susceptible for treat-
ment with trastuzumab (Herceptin, Roche, 
Penzberg, Upper Bavaria, Germany), which is a 
humanized monoclonal antibody raised against 
the extracellular domain of the HER2 protein. 
Herceptin is currently the standard first-line 
treatment toward metastatic breast cancer, 
and it is also indicated that therapeutic activity 
of Herceptin was enhanced when it applied as 
an adjuvant setting with other chemotherapeu-
tics [6, 7]. Up to date, the HER2 status might be 
sole factor indicating that patients are likely to 
respond to Herceptin. Based on the clinical 
results, Herceptin was approved by the Food 
and Drug Administration (FDA) of U.S.A. as a 
therapeutic drug in 1998 for treatment of 
advanced breast cancer. Actually, Herceptin 
consuming, expensive, difficult to screening 
multiple samples in a short time, and require a 
high-resolution fluorescence microscope. 
Moreover, these methods are difficult to stan-
dardize across laboratories [12, 13]. There- 
fore, it is necessary to develop a precise quan-
titative method to measure HER2 expression 
that are complementary to the IHC and FISH 
test.
Molecular techniques based on the quantita-
tive evaluation of HER2 messenger RNA (mR- 
NA) have been proposed. Especially, a reverse 
transcription quantitative PCR (RT-qPCR) was 
successfully used to evaluate the expression 
levels of HER2 mRNA in FFPE tissue samples. 
In this study, we employed the RT-qPCR method 
using a commercial diagnostic kit called 
‘BrightGen HER2 RT-qDx’ (Syantra, Calgary, 
Canada), for quantification of HER2 expression 
and comparison with standard IHC and FISH 
Figure 1. Analytical sensitivity of HER2 mRNA RT-qPCR. A. Analytical sensi-
tivity of HER2 mRNA RT-qPCR was determined using serially diluted breast 
cancer HER2 over-expressing SK-BR3 cells. B. HER2 mRNA RT-qPCR was 
performed three times and the mean Ct value was calculated (*N.D.; Not 
detected).
prolonged survival time of the 
patients having operable HER2-
positive cancer [8].
There are several reports com-
pared HER2 status between in 
the primary tumors and in the 
matched metastatic regions; 
the results indicated that there 
was an acceptable level of con-
cordance for HER2 expression 
between the two tumor regions 
(concordance rate = 80-94%) [9, 
10]. For this reason, the HER2 
test is important for targeted 
therapy in breast cancer pa- 
tients. The determination of 
HER2 status on primary tumor 
tissues is routinely performed 
by immunohistochemistry (IHC) 
or fluorescence in situ hybridiza-
tion analysis (FISH). IHC is car-
ried out on formalin-fixed paraf-
fin-embedded (FFPE) breast can- 
cer tissue samples to screen 
HER2 status in a clinical setting 
[11]. When the IHC score is 2+, 
HER2 gene amplification is 
detected by FISH. These two 
methods are standard for test-
ing the expression of HER2. 
Although these are reliable 
methods, IHC/FISH are time-
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methods using a total number of 199 FFPE 
breast cancer tissue samples.
Materials and methods
Clinical samples
A total of 199 FFPE tissue samples obtained 
from patients diagnosed with breast cancer at 
Yonsei University Severance Hospital (Seoul, 
Republic of Korea) for 2 years were analyzed in 
this study. With all patient tissues, IHC was 
already performed to verify expression of HER2, 
estrogen receptor (ER), and progesterone 
receptor (PR). All subjects provided written 
informed consent and the study was approved 
by the Institutional Ethics Committee of Yonsei 
University Severance Hospital (approval num-
ber 1-2010-0018).
Cell lines and cell culture
Human breast carcinoma cell line SK-BR3, 
which over-expresses HER2, was obtained from 
the Korean Cell Line Bank (Seoul, Republic of 
Korea). Human breast carcinoma cell line MCF7 
and MDA-MB-231, both of which weakly ex- 
presses HER2, were kindly provided by the 
Yonsei University Cancer Center (Seoul, Re- 
public of Korea). THP-1 human monocytic cell 
line, which weakly expresses HER2, was kindly 
provided by Yonsei University College of 
100 U/mL of penicillin, and 100 μg/mL of strep-
tomycin (Gibco-BRL, Carlsbad, California, USA).
Deparaffinization of FFPE tissue and total RNA 
isolation
In order to remove paraffin from FFPE tissue 
samples, two pieces of 10-µm-thick FFPE 
breast cancer tissue sections were put into a 
1.5-mL microcentrifuge tube, to which 1 mL of 
100% xylene was added. After shaking and vor-
texing, the tube was heated for 5 min at 50°C 
to melt the paraffin and centrifuged for 2 min at 
room temperature at 20,000 x g to precipitate 
the tissue. After centrifugation, xylene solution 
was removed, and then 1 mL of 100% EtOH 
was added to the precipitated tissue. This tube 
was centrifuged at 20,000 x g for 2 min at room 
temperature. After that, EtOH was carefully dis-
carded without disturbing the pellet. The EtOH 
washing was repeated twice. In the final wash-
ing, residual EtOH was removed as much as 
possible without disturbing the pellet, and the 
pellet was dried in the air for 25 min.
MagNA Pure LC RNA Isolation Kit III-Tissue 
(Roche Diagnostics, Mannheim and Penzberg, 
Germany) was used for total RNA extraction. In 
brief, 140 μL of tissue homogenized buffer 
(Roche Diagnostics) and 16 μL of 10% SDS 
solution were added to the deparaffinized tis-
sue, sequentially. Then, the mixed samples 
were vortexed and incubated overnight at 55°C, 
after which 220 μL of tissue lysis buffer (Roche 
Diagnostics) was added to the tissue lysate 
supernatant. Finally, MagNA Pure LC 2.0 (Roche 
Diagnostics) machine was used to purify total 
RNA from the tissue lysates. The purity and 
concentration of total RNA were determined by 
measuring the absorbance at 260 nm and 280 
nm using the Infinite 200® spectrophotometer 
(Tecan, Salzburg, Austria). All steps in the prep-
aration and handling of total RNA were con-
ducted in a laminar flow hood under RNase-
free conditions. The isolated total RNA was 
stored at -70°C until used for cDNA synthesis.
Table 1. Relative HER2 mRNA expression levels detected by 
HER2 mRNA RT-qPCR in various cell lines
Cell line HER2 status Origin of cell Relative HER2 mRNA expression level
SK-BR-3 Over-expressing Breast cancer 56.99 ± 7.34
MCF-7 Weak-expressing Breast cancer 5.43 ± 2.25
MDA-MB-231 Weak-expressing Breast cancer 1
THP-1 Weak-expressing Monocyte 0.7 ± 0.2
Table 2. Comparison of HER2 mRNA RT-qPCR 




No. of samples (%) Total
Positive Negative
3+ 29 (96.7) 1 (3.3) 30 (100)
2+/FISH+ 11 (84.6) 2 (15.4) 13 (100)
2+/FISH- 28 (45.9) 33 (54.1) 61 (100)
0/1+ 5 (10.2) 44 (89.8) 49 (100)
Total 73 (47.7) 80 (52.3) 153 (100)
Medicine (Seoul, Republic of 
Korea). The SK-BR3, MCF7, and 
MDA-MB-231 cancer cells were 
maintained as monolayer cul-
tures in DMEM at 37°C, 5% CO2. 
THP-1 cells were cultured in 
RPMI 1640 supplemented with 
2 mM glutamine. All the culture 
media were supplemented with 
10% fetal bovine serum (FBS), 
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cDNA synthesis
Complementary DNA (cDNA) was synthesized 
using an M-MLV Reverse Transcriptase kit 
(Invitrogen, Carlsbad, CA, USA) and random 
hexamers (Invitrogen) according to the manu-
facturer’s recommendations. Briefly, 10 μL of 
total RNA was added to the master mix contain-
ing 1 μL of 10 mM dNTP mix (10 mM each dATP, 
dGTP, dCTP, and dTTP at a neutral pH), 0.25 μg 
of random hexamers, and 5 μL of DEPC-treated 
water in PCR tubes. The reaction mixture was 
incubated at 65°C for 5 min, and then quickly 
chilled on ice. Subsequently, a mixture of 4 μL 
of 5× first-strand buffer, 2 μL of 0.1 M dithioth-
reitol (DTT), and 1 μL of M-MLV reverse tran-
scriptase (RT) was added to the reaction mix-
ture in PCR tubes, and the cDNA synthesis 
reaction was performed at 25°C for 10 min, 
37°C for 50 min, and 70°C for 15 min.
HER2 mRNA RT-qPCR assay (BrightGen HER2 
RT-qDx assay)
The HER2 mRNA expression level relative to 
GAPDH mRNA level was measured by RT-qPCR 
employing TaqMan probes using the CFX-96 
real-time PCR system (Bio-Rad, Hercules, CA, 
USA), which was used for thermo-cycling and 
fluorescence detection. The RT-qPCR TaqMan 
assay was carried out with the BrightGen HER2 
RT-qDx assay kit (Syantra) according to the 
manufacturer’s recommendations. Real-time 
PCR amplification for HER2 mRNA was per-
formed using a total volume of 20 μL that con-
tained 10 μL of 2× Thunderbird probe qPCR mix 
(Toyobo, Osaka, Japan), 5 μL of primer and 
TaqMan probe mixture, 2 μL of template cDNA, 
and D.W. to give a final volume of 20 μL for each 
sample. Positive and negative controls were 
included throughout the procedure. No- 
template controls with sterile D.W. instead of 
template DNA were incorporated into each run 
under the following conditions: 95°C for 3 min, 
followed by 40 cycles of 15 sec at 95°C and 30 
sec at 55°C. The mRNA expression level was 
quantified by determining the cycle threshold 
(CT), which is the number of PCR cycles required 
for the fluorescence to exceed a value signifi-
cantly higher than the background fluores-
Table 3. Clinical cut-off values of HER2 mRNA RT-qPCR obtained by ROC curve analysis with GAPDH 
Ct value below 30
Relative HER2 mRNA 
expression level Sensitivity % 95% CI Specificity % 95% CI Likelihood ratio
> 73.9 93.0 80.9% to 98.5% 83.7 70.3% to 92.7% 6.5
> 78.1 93.0 80.9% to 98.5% 85.7 72.8% to 94.1% 9.1
> 105.5 93.0 80.9% to 98.5% 89.8 80.4% to 97.7% 11.4
> 135.1 90.7 77.9% to 97.4% 91.8 80.4% to 97.7% 11.1
Abbreviations: ROC, Receiver operating characteristic; CI, Confidence interval.
Figure 2. Evaluation of HER2 mRNA RT-qPCR accord-
ing to the HER2 IHC and FISH score. FFPE breast 
cancer tissue samples were grouped by HER2 IHC 
and FISH results. The P-values between HER2 IHC 
negative and positive samples were calculated using 
one-way ANOVA (P < 0.0001).
HER2 mRNA expression in breast cancer tissues
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cence. To avoid false negatives due to degrada-
tion of mRNA, the reference gene, glycerald- 
ehyde-3-phosphate dehydrogenase (GAPDH), 
was used as a control. Target gene mRNA 
expression levels relative to GAPDH were auto-
matically calculated using the comparative Ct 
method by CFX Manager Software v1.6 (Bio-
Rad) or Genex Software (Bio-Rad), and the cut-
off value for distinguishing between positive 
and negative results was a relative HER2 mRNA 
expression level of 100.
Statistical analysis
For statistical data analysis, the software 
PRISM 5 Software (GraphPad, La Jolla, CA, 
USA) was used. In order to determine the statis-
tical significance of data, Student’s t-test and 
one-way ANOVA were carried out for the two-
group comparison and multiple-group compari-
son, respectively. Receiver operating charac-
teristic (ROC) curve analysis between conven- 
tional HER2 IHC, FISH and HER2 mRNA 
Data expressed as relative HER2 mRNA levels 
were calculated based on the basal expression 
level of HER2 in MDA-MB-231 cell line having 
low HER2 expression. Thus, fold increase of 
HER2 expression is relative value to the HER2 
expression that is set 1.0 in MDA-MB-231 cells. 
As we expected, SK-BR3, a HER2 over-express-
ing cell line, exhibited 57-fold higher HER2 
mRNA expression, whereas, monocyte cell line 
THP-1, a cell line weakly expressing HER2, 
exhibited 0.7-fold expression of HER2 mRNA 
(Table 1).
Expression levels of HER2 mRNA in the clinical 
specimens
In order to determine whether BrightGen HER2 
RT-qDx was useful to detect HER2 expression 
in FFPE clinical specimens, a total number of 
199 FFPE samples from breast cancer patients 
who had IHC scores were subjected to RT-qPCR 
analysis of HER2 and GAPDH.
Figure 3. Correlation coefficient analysis between the HER2 mRNA RT-
qPCR results and HER2 IHC and FISH results. The correlation between 
HER2 mRNA RT-qPCR and HER2 IHC and FISH results was good (Pearson 
r = 0.5418, r2 = 0.2936, P < 0.0001).
RT-qPCR was performed for all 
data.
Results
Analytical sensitivity of the RT-
qPCR for HER2 mRNA detection 
using reference breast cancer 
cell lines
In order to test whether the 
BrightGen HER2 RT-qDxI used in 
this study was able to detect 
HER2 mRNA expression quanti-
tatively, cDNA of breast cancer 
cell SK-BR3, which expresses 
high levels of HER2, was 10-fold 
diluted serially from 1×105 cells/
mL to 1 cell/mL. HER2 mRNA 
RT-qPCR was performed three 
times, and the mean Ct values 
from serially diluted SK-BR3 
cDNA are show in Figure 1. The 
mean Ct values of RT-qPCR 
using 105, 104, 103, 102, 10, and 
1 cell(s)/mL were 19.45, 23.20, 
26.49, 29.79, 33.35, and 36.08, 
respectively. The Ct value from 
the blank control reaction did 
not show any signal in any of the 
experiments (Figure 1).
HER2 mRNA expression in breast cancer tissues
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According to the BrightGen HER2 RT-qDxI anal-
yses, the samples having HER2 IHC 0 score 
showed relative HER2 mRNA expression levels 
from 4.5 to 395 (average, 83.7). And the sam-
ples having HER2 IHC 1+ score showed relative 
HER2 mRNA expression levels from 0.5 to 401 
(average, 86.6). The HER2 IHC score 2+/FISH- 
samples showed relative HER2 mRNA expres-
sion level from 0.01 to 813 (average, 198.1). In 
the HER2-positive groups, IHC 2+/FISH+ sam-
ples, showed relative HER2 mRNA expression 
level from 13.3 to 2711 (average, 709.4), and 
HER2 IHC 3+ samples showed relative HER2 
mRNA expression levels from 22.5 to 4850 
(average, 1936.7) (Figure 2).
Diagnostic cut-off determination of HER2 
mRNA RT-qPCR assay
ROC analysis was performed to determine the 
optimal diagnostic cut-off value for clinical use. 
For ROC analysis, both of the HER2 mRNA lev-
els obtained with the BrightGen HER2 RT-qDx 
analyses and the HER2 IHC score were used. 
The 199 FFPE samples were divided into two 
groups: HER2 IHC-positive and HER2 IHC-
negative. Samples having IHC scores greater 
than 2+ and FISH+ were included in the HER2 
IHC-positive group. Samples having IHC scores 
of 0 and 1+ were included in the HER2 IHC-
negative group. IHC 2+ and FISH- samples were 
excluded from the analysis for its inconsistent 
results between the two assays.
Sensitivity and specificity of the ROC analysis 
were expressed by the area under curve (AUC) 
value. Among the 199 FFPE breast cancer tis-
sue samples, 153 samples had GAPDH Ct 
value below 30. The highest AUC value was 
obtained from the samples having GAPDH Ct 
values below 30 indicating the highest sensitiv-
ity and specificity (AUC = 0.9466). According to 
the ROC analysis, the cut-off value of HER2 
RT-qPCR was determined by likelihood ratio 
(Table 3). The highest likelihood ratio was the 
relative HER2 mRNA levels over 105.5 fold, 
indicating highest sensitivity and specificity. 
Based on this result, samples with a relative 
HER2 mRNA expression level greater than 
105.5 by HER2 RT-qPCR assay were consid-
ered positive in this study (Table 3).
Comparison of the RT-qPCR results with IHC 
and FISH results for HER2 expression
Among the HER2-positive samples decided by 
IHC or IHC/FISH (HER2 IHC 3+ and IHC 2+/
FISH+), all the samples were positive with HER2 
RT-qPCR except 3 samples. Among the HER2-
negative samples (HER2 IHC 0 and 1+), 44 
samples were negative and 5 samples were 
detected positive with the RT-qPCR. Therefore, 
the overall sensitivity and specificity of the 
BrightGen HER2 RT-qDx were 93.0% and 
89.8%, respectively (Table 2). The P-values 
between HER2 IHC negative and positive were 
statically significant (P < 0.0001) via one-way 
ANOVA test when it was decided by the results 
from the RT-qPCR analyses.
Correlation level between the RT-qPCR and 
HER2 IHC/FISH score for detection of HER2 
expression
In order to verify the correlation between rela-
tive HER2 mRNA expression level and HER2 
IHC/FISH score, correlation coefficient analysis 
was performed using clinical samples having 
GAPDH Ct value below 30 (Figure 3). For the 
analysis of the correlation coefficient, the HER2 
IHC test results were given as scores: a HER2 
IHC score of 0 for 0, a HER2 IHC score of 1+ for 
25, a HER2 IHC score 2+/FISH- for 50, a HER2 
IHC score 2+/FISH+ for 75, and a HER2 IHC 
score of 3+ for 100. Then, HER2 mRNA RT-qPCR 
results of FFPE breast cancer tissue samples 
were compared with the HER2 IHC/FISH test 
results. The data showed that there was a cor-
relation between relative HER2 mRNA expres-
sion levels and standard HER2 IHC/FISH test 
results (Pearson r = 0.5408, r2 = 0.2936, P < 
0.0001) (Figure 3).
Discussion
IHC and FISH are regarded as standard assays 
for detection of HER2 expression in breast can-
cer samples. Determination of HER2 expres-
sion is essential for application of Herceptin-
mediated therapy to breast cancer patients. In 
particular, IHC has been widely used for its mul-
tiple application to screening, diagnosis, and 
cancer stage determination. Nevertheless, IHC 
has fundamental weakness: it uses antibody to 
detect target protein in cell and tissue samples, 
so that IHC requires a long process time and 
there are variations between each laboratories 
[14]. And the intensity of IHC is decided depend-
ing on the enzyme activity of horseradish per-
oxidase (HRP) that is conjugated on antibodies. 
Therefore, the staining intensity may be influ-
enced by reaction time, temperature, and HRP 
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substrate concentrations [16]. For HER2 detec-
tion, IHC provides reliable results with 0/1+ 
indicates HER2-negative status and 3+ indi-
cates HER2-positive status in the samples. In 
case of 2+ score by HER2 IHC, the samples 
should be further tested by FISH to confirm 
HER2 status [15]. FISH assay also has weak-
nesses: since it uses fluorescent dyes, the 
stained slides cannot be preserved a long time, 
and FISH assay need a high-resolution fluores-
cent microscope that is not equipped in every 
hospital laboratory [17].
To complement the weaknesses of IHC/FISH 
methods, we evaluated a RT-qPCR method 
using a new RT-qPCR assay kit, BrightGen 
HER2 RT-qDx assay, with which accuracy and 
sensitivity of the RT-qPCR method were com-
pared with IHC/FISH for HER2 detection. We 
expected that RT-qPCR method could be stan-
dardized and reduce variances between labo-
ratories for quantification of HER2 expression 
in clinical samples because RT-qPCR assay has 
strength for quantitating target gene mRNA 
expression level. RT-qPCR is also recommend-
ed by the Clinical and Laboratory Standards 
Institute (CLSI) guidelines, and it is highly sensi-
tive and specific because primers and probes 
are target gene sequence-specific [18]. In this 
study, HER2 mRNA expression levels were 
expressed as a fold induction in reference to 
expression of a housekeeping gene, GAPDH. 
Therefore, obtaining the minimum Ct value of 
the GAPDH gene expression level from speci-
mens influenced the sensitivity and specificity 
of the assay. In this study, only the Ct values 
below 30 were used for GAPDH mRNA RT-qPCR 
(Table 3).
We compared the RT-qPCR results for HER2 
expression with that from the current standard 
methods, IHC and FISH. The overall sensitivity 
of the RT-qPCR was 93.0% and the specificity 
was 89.8% (Figure 3 and Table 3). Some of the 
samples showing HER2 IHC 2+/FISH- were pos-
itive by the RT-qPCR. We don’t know the reason 
for the inconsistency clearly, but there might be 
lost of HER2 mRNA in the samples while the 
HER2 protein remained. In the previous studies 
[19, 20], it has been reported that Herceptin 
had an effect on the patients with HER2 IHC 
2+/FISH-. In our study, there were 61 (39.9%) 
out of 153 samples from the breast cancer 
patients had HER2 IHC 2+/FISH-. Although, all 
of the 61 patients are not subjected to 
Herceptin treatment, 28 patients (45.9%) were 
detected positive by the current RT-qPCR analy-
ses. Those 28 patients might have high possi-
bility to be susceptible to Herceptin treatment.
In conclusion, this study shows that the 
RT-qPCR method produced quite correlated 
results with that from the conventional IHC/
FISH methods with some exception of the 
IHC2+/FISH- samples. Because PCR-based 
analyses employed sequence-specific primers 
and probes for target DNA, we expect that there 
is much room for improvement of sensitivity 
and specificity of the RT-qPCR method by devel-
oping new primers and probes. As long as the 
quality is guaranteed, RT-qPCR method could 
be the first choice for determining HER2 expres-
sion in clinical samples of breast cancer 
patients.
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